Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer
| Class:Id | LiteratureReference:2011995 |
|---|
| _displayName | FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer |
|---|
| _timestamp | 2011-11-22 14:55:11 |
|---|
| author | [Person:1301684] Turner, N
[Person:2011678] Pearson, A
[Person:2011734] Sharpe, R
[Person:2011632] Lambros, M
[Person:2011572] Geyer, F
[Person:2011641] Lopez-Garcia, MA
[Person:2011670] Natrajan, R
[Person:2011649] Marchio, C
[Person:2011603] Iorns, E
[Person:2011646] Mackay, A
[Person:2011573] Gillett, C
[Person:2011579] Grigoriadis, A
[Person:2011768] Tutt, A
[Person:2011697] Reis-Filho, JS
[Person:110798] Ashworth, A |
|---|
| created | [InstanceEdit:2011994] Rothfels, K, 2011-11-22 |
|---|
| journal | Cancer Res |
|---|
| pages | 2085-94 |
|---|
| pubMedIdentifier | 20179196 |
|---|
| title | FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer |
|---|
| volume | 70 |
|---|
| year | 2010 |
|---|
| (literatureReference) | [Pathway:1226099] Signaling by FGFR in disease [Homo sapiens]
[Pathway:1839120] Signaling by FGFR1 amplification mutants [Homo sapiens]
[Reaction:2023462] Tyrosine kinase inhibitors bind and inhibit overexpressed FGFR1 dimers [Homo sapiens]
[Reaction:5655241] Activated FGFR2 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange [Homo sapiens]
[Reaction:5655277] Activated FGFR3 point, translocation and fusion mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange [Homo sapiens]
[Reaction:5655326] Activated FGFR1 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange [Homo sapiens]
[Reaction:5655347] Activated FGFR4 mutants:p-FRS2:GRB2:SOS1 activates RAS nucleotide exchange [Homo sapiens] |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer (2011995)
